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Male-to-female ratio was 5:2. In more than 90% of cases, the
pathology was squamous-cell carcinoma. Adenosquamous carci-
noma and adenocarcinomawere less than 10%. Cancers staged as
IV, III, and II made up 38.2%, 53.7%, and 10.1% of cases, respec-
tively, and 23.6% of cases involved metastasis. 22 patients
(2.63%) had adverse reactions that were unlikely to be due to nim-
otuzumab, including chills and fever in eight cases (0.96%), rash
in five cases (0.6%), oral mucositis in three cases (0.36%), gastroin-
testinal symptoms (vomiting or diarrhoea) in two cases (0.24%),
and dizziness in one case (0.12%). One patient had significant fati-
gue (0.12%), five had thrombocytopenia (0.6%), and five had
decreased white blood-cell count. Nimotuzumab-induced allergy
occurred in one case (0.12%).
Interpretation: Nimotuzumab combined with chemotherapy,
radiotherapy, or chemoradiotherapy for patients with advanced
carcinoma is well tolerated and safe.
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Background: We evaluated clinical outcomes and acute toxicity
in nasopharyngeal carcinoma treated with tomotherapy followed
by anti-EGFR monoclonal antibodies.
Methods: Between March, 2008, and November, 2009, 34
patients with newly diagnosed nasopharyngeal carcinoma were
treated with helical tomotherapy combined with nimotuzumab
(group N) or cetuximab (group C). All patients received tomother-
apy at 70 Gy/33F for the gross tumour volume (pGTVnx) and posi-
tive lymph nodes (GTVnd), 60Gy/33F for the high-risk clinical
target volume (CTV1), and 56 Gy/33F for the low-risk clinical tar-
get volume (CTV2). 17 patients in group N were given a weekly
injection of 200 mg/m2 for 6–7 weeks, and 17 patients in group
C were given an initial intravenous dose of 400 mg/m2 in the first
week, followed by weekly injections of 250 mg/m2 for 6–7 weeks.
Acute lesions were evaluated with the RTOG/EORTC criteria.
Findings The median follow-up was 22 months. Effective rates
(complete + partial responses) at 3, 6, and 12 months were 82.4%
(14/17), 70.6% (12/17), and 70.6% (12/17) in group N, and 88.2%
(15/17), 82.4% (14/17), and 82.4% (14/17) in group C. 1-year survival
was 88.2% (15/17) in group N and 100% (17/17) in group C. Nim-
otuzumab was associated with less acute mucositis (u = 2.245,
p < 0.05), weight loss (t 0 = 2.563, p = 0.0153) and rash (u = 4.362,
p < 0.01) than cetuximab.
Interpretation: Helical tomotherapy combined with nim-
otuzumab or cetuximab was effective for nasopharyngeal
carcinoma, and there was no difference in short-term efficacy
or 1-year survival. Nimotuzumab has fewer acute reactions than
cetuximab. More studies should be done to ascertain the long-
term effects.
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Background: We explored the efficacy of biological targeted
therapy combined with chemotherapy.
Methods: 71 patients (54 men and 17 women; age 30–83 years,
mean 60) were enrolled in this study. All patients had locally
advanced oral-maxillofacial and head and neck tumours (no indi-
cation for surgery or radiotherapy) confirmed by histology and
radiology, with indication for biochemotherapy. The chemother-
apy regimen given was cisplatin 75 mg/m2 day 1, paclitaxel
75 mg/m2 day 1, fluorouracil 750 mg/m2 days 1–5, and nim-
otuzumab 200 mg/m2 weekly.
Findings: Patients completed 2–4 cycles of chemotherapy
(mean 2.2). Nimotuzumab was given 2–8 times (mean 4.3). The
prognosis was as follows: complete response in four patients, par-
tial response in 39, stable disease in 18, and progressive disease in
3. Seven patients could not be evaluated. The total effective rate,
calculated as complete plus partial responses, was 61%. 29
patients had surgery after biochemotherapy. No serious adverse
reactions were noted during the course of the treatment, only
one case of slight erythra infection.
Interpretation: Nimotuzumab was effective in increasing
chemosensitivity and had a good tolerability profile.
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Background: Concurrent chemoradiotherapy is the standard
treatment for non-surgical care of patients with locally advanced
oesophageal cancer. Nimotuzumab (h-R3) is a genetically engi-
neered humanised monoclonal antibody that can recognise an
epitope in the extracellular domain of human epidermal
growth-factor receptor (EGFR). This phase 1 trial was designed
to assess the safety and efficacy of nimotuzumab when given
with concurrent chemoradiotherapy.
Methods: Patients age 18–75 years, with ECOG performance sta-
tus 0–2 and locally advanced squamous oesophageal cancer con-
firmed by histological assay, were eligible for the study. Patients
received radiotherapy to a total dose of 61.2 Gy/32Fx concurrent
with two cycles of PF regimen (cisplatin 25 mg/m2 days 1–3; fluoro-
uracil 600 mg/m2 continuous IV infusion days 1–3, every 28 days).
An escalating weekly fixed dose of nimotuzumab (100, 200, and
400 mg) was administered during radiotherapy in a cohort study.
After radiotherapy, patients received consolidation chemotherapy
with PF regimen every 28 days for another two cycles. The primary
endpointswere safety and early efficacy. The trial was approved by
the Chinese State Food and Drug Administration and the protocol
has passed ethical committee review and gained institutional
review board permission. The trial is registered with clinicaltri-
als.gov, number NCT00950417. All participants gave written
informed consent.
Findings: From July, 2009, to June, 2010, nine patients (seven
men and two women) with a median age of 58 years (48–72 years)
were enrolled. All patients tolerated the treatment. No adverse
events likely to be related to nimotuzumab were noted. The
objective remission rate, which can reflect early efficacy, was
66.67–75% based on the evaluable cases.
Interpretation: Nimotuzumab combined with chemoradiother-
apy based on the PF regimen was safe and well-tolerated.
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Background: Nimotuzumab is a humanised monoclonal anti-
body of epidermal growth-factor receptor (EGFR). We assessed
the safety, tolerability, and efficacy of nimotuzumab combined
with irinotecan as second-line treatment in Chinese patients with
metastatic colorectal cancer (mCRC).
Methods: Patients with mCRC refractory to oxaliplatin, wild-
type K-ras, target lesion(s), ECOG performance status 62, and
adequate organ function were eligible for this open-label, sin-
gle-arm trial (NCT00972465). Irinotecan was given as 180 mg/m2
on day 1 every 2 weeks until progression, or adverse events, for
a maximum of six cycles. Nimotuzumab was given as 200, 400,
or 600 mg weekly until progression or adverse events. Primary
endpoints were objective response rate and toxicity. Secondary
endpoints were progression-free and overall survival. Patients
gave written informed consent.
Findings A total of 22 patients (male-to-female ratio 14:8; med-
ian age 55 years, range 30–78) were enrolled from July, 2009, to
July, 2010. Four, seven, and 11 patients received nimotuzumab
at a dose of 200, 400, and 600 mg, respectively. The total number
of doses of nimotuzumab was 244 (median 6, range 2–30). No
grade 3–4 toxic effects relating to nimotuzumab were observed.
Two patients developed skin rash (grade 1): one each at the 400
and 600 mg doses. The maximum tolerated dose has not yet been
reached. Three patients (two at the 400 mg dose and one at
600 mg) dropped out for personal reasons. In the 600 mg group,
partial response was 40% (4/10) and progressive disease (PD)
was 60% (6/10). In the 400 mg group, stable disease (SD) was
20% (1/5) and PD was 80% (4/5). In the 200 mg group, SD was
50% (2/4) and PD was 50% (2/4). Follow-up of overall survival is
ongoing.
Interpretation: Addition of nimotuzumab 600 mg weekly to
irinotecan for second-line treatment of mCRC is safe, and first
data suggest promising activity. The maximum tolerated dose of
nimotuzumab has not been reached yet.
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Background: Nimotuzumab, a humanised anti-epidermal
growth-factor receptor (EGFR) monoclonal antibody, has demon-
strated efficacy and an absence of severe skin toxicity in many
phase 1 and 2 cancer trials.
Methods: We did a single-centre, randomised, parallel assign-
ment, open-label study of nimotuzumab (N: 200 mg IV on days
1, 8, and 15, every 3 weeks) plus cisplatin (C: 30 mg/m2 on days
1 and 2, every 3 weeks) plus S-1 (S: 80 mg/m2 twice daily on days
1–14, followed by 7 days off) versus cisplatin plus S-1, as first-line
treatment in patients with advanced or metastatic gastric cancer.
If tumour control was achieved, NCS and CS were continued until
unacceptable toxicity or disease progression. The primary end-
point was objective response rate (ORR) and the secondary end-
points included time-to-progression (TTP), progression-free
survival (PFS), 1-year survival rates, and safety.
Findings: 40 patients, 27 men and 13 women, with a median
age of 54 years (range 21–74) and good performance status (ECOG
PS 0–2) were treated with NCS (n = 20) or CS (n = 20). Up to January
14, 2011, 36 patients (NCS group 19 cases, CS group 17 cases) have
undergone efficacy assessment. ORR was 63.2% (12/19) in the NCS
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